Mr. Leo Redmond Joins Presidio Pharmaceuticals as Chief Financial Officer

Former Genentech, Inc. Senior Director to Oversee Financial Operations

San Francisco, CA - January 7, 2008 - Presidio Pharmaceuticals, Inc. announced today the appointment of Mr. Leo Redmond to the position of Chief Financial Officer. Mr. Redmond brings 20 years of financial experience to Presidio.

For the past 16 years, Mr. Redmond served in a variety of roles of increasing responsibility at Genentech. Most recently he was Senior Director of Finance, where he was responsible for the Financial Systems organization. In addition, Mr. Redmond performed financial planning, accounting, operations and reporting roles, and supported the R&D, commercial, administrative and business development groups at Genentech. He also served as CFO and Secretary for the Genentech Foundation for Biomedical Sciences.

"I am very pleased to have Leo join our organization," stated Dr. Omar K. Haffar, President and Chief Executive Officer of Presidio Pharmaceuticals. "Leo brings a great deal of experience in establishing solid financial processes and systems for growing companies, from his many years at Genentech. Importantly, his diversified and broad expertise in accounting and finance is in line with Presidio's growth plans. He will be able to support both Presidio's current business development initiatives as well as our future plans to establish a sales and marketing presence in the industry."

"It is with great enthusiasm that I join Presidio Pharmaceuticals at this time," commented Mr. Redmond. "This group of talented and dedicated people is working on promising new therapies to treat diseases that affect millions of people worldwide. I look forward to contributing to the continued success of the company by helping Presidio expand its financial capabilities to allow it to achieve its strategic and operational goals."

It was also announced today that Antoun Nabhan, J.D. will move to his new role as Vice President Operations and Investor Relations at Presidio.

About Presidio Pharmaceuticals:
Presidio Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on discovering, in-licensing, developing and commercializing novel therapeutics for viral infections, including but not limited to HIV-l and HCV. Presidio has raised over $27 million in financing from Panorama Capital (formerly JP Morgan Partners), Baker Brothers Investments, Bay City Capital, Ventures West, Nexus Medical Partners, and Sagamore Bioventures.

For more information, please visit our website at www.presidiopharma.com